The inhibitory domains of calpastatin contain three highly conserved regions, A, B and C, of which A and C bind calpain in a strictly Ca 2+ -dependent manner but have no inhibitory activity whereas region B inhibits calpain on its own. We synthesized the 19-mer oligopeptides corresponding to region A and C of human calpastatin domain I and tested their effect on human erythrocyte µ-calpain and rat m-calpain. 
Introduction
Calpains represent a superfamily of proteases related by their homology in a papain-like protease domain (1, 2) . Several members of this family, such as the best studied typical forms, µ-and m-calpain, are thought to be activated by a Ca 2+ signal; their activation then leads to the limited proteolytic modification of a variety of substrate proteins. Recent X-ray crystallographic studies of rat (3) and human (4) m-calpain have revealed the structural background of the Ca 2+ -dependence of calpain activity. Without Ca 2+ the structure of the active site is distorted; largescale conformational changes have to occur for the assembly of a catalytically competent active site. Although mechanistically clear, key aspects of the activation process in vivo are still enigmatic as calpains require non-physiologically high Ca 2+ concentrations in vitro: µ-and mcalpains reach half-maximal activation in the high µM to mM free Ca 2+ concentration range (cf.
(5)), hardly attainable under normal cellular conditions.
Several suggestions have been put forward how to close this gap. First, calpain undergoes autolytic activation with a concomitant sensitization to Ca 2+ (5, 6) ; this, of course, does not alleviate the initial high Ca 2+ requirement. Second, phospholipids increase calcium sensitivity of calpain (7, 8) and activation probably involves the translocation of the enzyme to the plasma membrane (9,10). Third, calpain might also be sensitized to Ca 2+ by a specific activator protein that affects membrane localization and autolysis of the enzyme (11). Nuclear DNA, shown to promote calpain effect on transcription factors and other nuclear proteins, may be another positive effector (12). The above factors have been characterized to different extents and there is no consensus with respect to their contribution.
In this paper we raise the possibility of a further, rather unexpected way of calpain sensitization to Ca 2+ by fragments of its endogenous inhibitor, calpastatin. 
Experimental Procedures

Enzymes
Human erythrocyte µ-calpain was purchased from Calbiochem (cat # 208713). Rat mcalpain composed of a 80K large subunit and a 21K truncated small subunit was expressed in E.
coli and purified via the C-terminal His-tag attached to its large subunit as given in (24) . The enzymes were dialyzed against three changes of 10 mM HEPES, 150 mM NaCl, 1 mM EDTA, 2 mM benzamidine, 0.2 mM PMSF and 15 mM β-mercaptoethanol (calpain buffer) and stored at 4 o C until use. On the day of use a small aliquot was taken out and reactivated with 15 mM β-mercaptoethanol for 1 hour prior to the experiments.
Peptides
The acetylated oligopeptide amides used in the present study correspond to subdomains A and C of human calpastatin inhibitory domain I (cf. Fig. 1 and (21) 
Calpain activity measurements
Calpain activity was measured in a Jasco FP 777 spectrofluorometer at excitation and emission wavelengths of 380 and 460 nm in a 3 x 3 mm quartz cuvette. The reaction mixture in 50 µl calpain buffer contained 1 mM LY-AMC as substrate at various peptide-and Ca software for determining the initial slope of fluorescence change; it was checked that this slope was proportional to enzyme amount/activity under the given conditions.
Materials
The fluorescent substrate LY-AMC (cat. # S 1153) and all other chemicals were purchased from Sigma Chemical Co. The buffer was prepared with ion-exchanged distilled water.
Results
To see if oligopeptides A and C have an effect on µ-calpain activity, an intermediate Ca
2+
concentration was used at which the enzyme activity could be conveniently measured but was significantly lower than that at saturating Ca 2+ concentrations (13% at 2.4 µM free Ca 2+
). At this Ca 2+ level the enzyme was titrated with increasing concentrations of a mixture of peptides A + C. Fig. 2 shows that the oligopeptides increase calpain activity about 5-fold with an EC 50 concentration around 7.5 µM. The concentration-dependence of activation has a slight sigmoidal shape, which hints at a cooperative effect between the two peptides. Subdomains A and C, when applied separately, also activate the enzyme ( Fig. 2 ): under the conditions used both increase the activity about 2-3-fold, with a half maximal effect around 15 µM concentration.
Activation of calpain at sub-saturating Ca 2+ concentration might result from the expected sensitization to Ca
, from a net increase in maximal activity without affecting Ca 2+ sensitivity, or both. To distinguish between these alternatives, the Ca 2+ -dependence of µ-calpain in the absence of peptides and in the presence of peptides at saturating concentration (40 µM each) was measured (Fig. 3A) . Activation is clearly due to a significant increase in Ca 2+ sensitivity of the enzyme: the concentration of half-maximal activity shifts from 4.3 to 2.4 µM upon the addition of peptide mixture. The maximal activity at saturating Ca 2+ concentrations, on the other hand, is unchanged within experimental error. With respect to the physiological activation of the enzyme, it is potentially very significant that an activation of about an order of magnitude is seen at low Ca 2+ concentrations (Fig. 3B) .
A similar set of experiments was carried out with m-calpain, i.e. with rat 80/21.
Subdomains A and C exert a qualitatively similar activating effect: at 140 µM free Ca
, where enzyme activity is 10% of that at saturating Ca 2+ concentrations, the peptides cause an about 5-fold activation of the enzyme (Fig. 4) . Half-maximal peptide concentration is somewhat higher (25 µM) and the course of activation has a more distinct sigmoidal shape than with µ-calpain. concentration of the peptides with no effect on maximal activity (Fig. 5A) . At low Ca 2+ concentrations the activation approaches one order of magnitude (Fig. 5B) .
Discussion
The results presented unequivocally demonstrate that peptides corresponding to subdomains A and C of human calpastatin domain I markedly sensitize both µ-and m calpain to Ca In structural terms this implies that the conformational change of the two subunits is functionally linked and occurs in a concerted manner. The peptide concentration needed for half-maximal effect is somewhat lower for µ-calpain (7.5 µM) than m-calpain (25 µM), which might be due to the different sensitivity of isoforms, but may also reflect species difference as the peptides are derived from human calpastatin. Either way, this difference indicates that the development of isoform-specific activator peptides is conceivable. Overall, our observations have three important implications.
The first implication relates to the issue of the activation of calpains under physiological Ca 2+ concentrations. As outlined in the Introduction, several factors may be involved in lowering the Ca 2+ demand of calpains. Although this issue is not settled yet, it seems that phospholipids (7, 8) , nuclear DNA (12), a specific activator protein (11) and autolytic processing of calpain itself (5,6) may all contribute to shifting the Ca 2+ need of calpain toward the physiological range.
Our findings, perhaps paradoxically, bring calpastatin, the specific calpain inhibitor, into this picture. In principle, it is possible that calpastatin is fragmented in such a way in vivo that degrades its inhibitory subdomain (B) but leaves activator subdomains A and C more-or-less
intact. Under such circumstances activation might override inhibition and calpastatin fragments stimulate calpain. Calpastatin is very sensitive to proteolysis in vitro (25) and is degraded by caspases (26) and calpain itself (27) Owing to this mechanism, fragments corresponding to the same amount of calpastatin subdomains A and C may give a much higher effective concentration in the cell than in dilute solution in the test tube and activate calpain at concentrations significantly lower than the values reported in this work.
The second general implication of our work is related to previous efforts at characterizing the physiological function of calpains. It is known from knockout experiments that calpains play an essential role as deletion of the ubiquitous small subunit is lethal in mice (32) . The role of various calpain forms has been extensively studied, almost invariably by the application of calpain inhibitors. From such studies we know that calpain(s) play a regulatory role in basic cellular processes such as the cell cycle (33), cell motility (34), cell spreading (35), apoptosis (36) and many more. The inhibitors, however, lack strict specificity: they may react with the proteosome, lysosomal proteinases, or even non-proteolytic enzymes (37, 38) . These findings have prompted the development of strictly specific calpain inhibitors (39) or the use of a cellpermeable variety of calpastatin subdomain B for cell biological studies. In general, the results 9 with calpain inhibitors can not always be unequivocally associated with the action of calpain.
Thus, it is desirable to develop activators for calpain based on our observations with subdomains A and C. As these peptides are highly charged, both subdomains have to be fused with "carrier"
peptides that make other substances membrane-permeable. The development of such constructs, which will probably complement the use of calpain inhibitors in further analysis of calpain function, is under way (patent pending).
The third implication worth considering is related to the pathological role of calpain.
Overactivation of calpain seems to be important in a range of disorders (37, 40) ; more recent findings, however, point to the link of diminished activity and the development of pathological states. Positional cloning in patients with limb girdle muscular distrophy 2A linked the gene of calpain 3 (p94) with this disease (41) . Later studies revealed that disease is associated with mutations in this gene, which invariably leads to a partial or complete loss of enzyme activity (42) . In a similar approach, diabetes mellitus type 2, which accounts for about 90% of the incidence of diabetes, was linked to the gene of calpain 10 (43); a single-nucleotide polymorphism within one intron of the gene is associated with a significantly reduced mRNA level (44) . Thus, the enzyme in this case is fully active, but it is expressed at a lower level. The two diseases, and possibly others, have in common a diminution in calpain activity; apparently, drugs that could boost activity might be beneficial.
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